Ufp Technologies (UFPT)
NASDAQ:UFPT
Top Page
Ufp Technologies
(NASDAQ:UFPT)
Select Model
Select Model
Rating:69Neutral
Price Target:
$231.00
▲(21.53% Upside)
Action:DowngradedDate:02/28/26
The score is driven primarily by strong underlying financial performance and a positive forward outlook from the latest earnings call, supported by a meaningful contract expansion that improves visibility. These positives are tempered by clearly weak technicals (price below key moving averages with negative MACD) and a valuation that is not inexpensive, while cash flow softness in 2025 is a key fundamental watch item.
Positive Factors
Revenue Growth
Sustained multi‑year revenue expansion (from ~$179M in 2020 to ~$603M in 2025) demonstrates scalable demand and successful market penetration. This scale supports fixed‑cost absorption, R&D and capacity investments, and makes growth less dependent on any single short quarter.
Negative Factors
Cash Flow Variability
Free cash flow fell nearly 10% in 2025 even as net income rose, and operating cash flow relative to revenue weakened, indicating working‑capital or timing pressures. Persistent cash conversion volatility can constrain reinvestment, dividend policy and reduces margin of safety during slowdowns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained multi‑year revenue expansion (from ~$179M in 2020 to ~$603M in 2025) demonstrates scalable demand and successful market penetration. This scale supports fixed‑cost absorption, R&D and capacity investments, and makes growth less dependent on any single short quarter.
Read all positive factors
Ufp Technologies (UFPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.47B
Dividend YieldN/A
Average Volume (3M)210.91K
Price to Earnings (P/E)25.0
Beta (1Y)1.37
Revenue Growth29.47%
EPS Growth23.24%
CountryUS
Employees4,146
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)2.25
Shares Outstanding7,713,300
10 Day Avg. Volume193,261
30 Day Avg. Volume210,907
Financial Highlights & Ratios
PEG Ratio1.63
Price to Book (P/B)4.04
Price to Sales (P/S)2.84
P/FCF Ratio21.66
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue2.65
Enterprise Value/Gross Profit9.39
Enterprise Value/Ebitda13.83
Forecast
1Y Price Target
$289.00Price Target Upside52.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)9.83
Revenue Forecast (FY)$640.22M
Ufp Technologies Business Overview & Revenue Model
Company Description
UFP Technologies, Inc. designs and custom manufactures components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics primarily for the medical market. Its single-use and single-patient devices and components a...
How the Company Makes Money
UFP Technologies generates revenue through the sale of its custom-engineered products, which are primarily focused on protective packaging, molded products, and specialty foam solutions. The company has multiple key revenue streams, including dire...
Ufp Technologies Key Performance Indicators (KPIs)
Ufp Technologies Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 05, 2026
Earnings Call Sentiment Positive
The call conveyed a broadly positive outlook driven by strong revenue growth (+19.5% to $602.8M), multi-year profitability gains (operating income +435%, EPS +419% since 2021), healthy cash generation (~$92M), debt reduction (~$53.9M) and multiple contract extensions and capacity expansions. These positives were tempered by meaningful near-term operational headwinds: a $6.3M AJR labor inefficiency that compressed gross margin, a recent ransomware attack causing temporary manual processes and potential shipment timing impacts, and low single-digit organic growth in 2025. Management emphasized that margins remained within target ranges after adjustments, that AJR inefficiencies are improving (Q4 $1.2M vs Q3 $3.0M), and that backlog and capacity expansions should support future growth. Overall, the highlights and durable strategic progress outweigh the transitory lowlights.Positive Updates
Strong Revenue Growth and Scale Milestone
Total revenue grew 19.5% for FY2025 to $602.8 million, representing nearly a 3x increase in revenue since 2021.
Negative Updates
AJR Labor Inefficiencies and Backlog
Labor inefficiencies at the Illinois AJR facility cost $6.3 million in 2025 (Q4 impact $1.2 million vs. Q3 $3.0 million); backlog in safe patient handling carried into 2026 and required overtime and temp staffing.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth and Scale Milestone
Total revenue grew 19.5% for FY2025 to $602.8 million, representing nearly a 3x increase in revenue since 2021.
Read all positive updates
Company Guidance
Management signaled continued growth and operational recovery for 2026 anchored to strong FY2025 metrics — sales +19.5% to $602.8M, EPS +15.4% for the year, adjusted operating margin 17.1% (within a 17–20% target), and gross margin 28.3% (would be 29.3% excluding a $6.3M AJR labor inefficiency, which included $1.2M in Q4 vs. $3.0M in Q3). They expect organic sales to build on low-single-digit 2025 levels into “robust” growth driven by patient services, double‑digit safe‑patient‑handling growth and multiple program launches (three recent program launches and expanded robotic surgery capacity), while the largest‑customer contract was extended two additional years (and an infection‑prevention contract funded through 2030) — specific volume and minimums were withheld by customer request. Management said the AJR headwind should be smaller in Q1 than Q4 and will diminish each quarter as backlog (not fully quantified but higher into 2026) is worked down; balance‑sheet strength supports the plan with ~ $92.0M cash from operations in 2025, $12.9M capex, ~$53.9M debt paid down to ~1.1x leverage, and only a modest February softness from a recent cyber incident expected to be made up in March.Ufp Technologies Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
74
Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 602.80M | 504.42M | 400.07M | 353.79M | 206.32M |
| Gross Profit | 170.41M | 146.69M | 112.22M | 90.26M | 51.11M |
| EBITDA | 115.74M | 95.80M | 68.95M | 67.37M | 29.65M |
| Net Income | 68.31M | 58.98M | 44.92M | 41.79M | 15.89M |
Balance Sheet | |||||
| Total Assets | 665.74M | 629.00M | 404.14M | 378.19M | 334.13M |
| Cash, Cash Equivalents and Short-Term Investments | 20.30M | 13.45M | 5.26M | 4.45M | 11.12M |
| Total Debt | 154.48M | 206.03M | 46.04M | 68.37M | 84.36M |
| Total Liabilities | 241.86M | 286.24M | 118.05M | 140.65M | 139.69M |
| Stockholders Equity | 423.88M | 342.76M | 286.09M | 237.54M | 194.45M |
Cash Flow | |||||
| Free Cash Flow | 78.98M | 56.94M | 30.84M | 3.96M | 8.90M |
| Operating Cash Flow | 91.91M | 66.59M | 41.33M | 17.74M | 14.29M |
| Investing Cash Flow | -27.60M | -210.16M | -10.49M | 1.29M | -101.46M |
| Financing Cash Flow | -58.16M | 152.39M | -30.02M | -25.89M | 74.05M |
Ufp Technologies Technical Analysis
Negative
190.07
Price Trends
234.12
Negative
229.35
Negative
223.94
Negative
Market Momentum
-11.69
Positive
28.82
Positive
7.65
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UFPT, the sentiment is Negative. The current price of 190.07 is below the 20-day moving average (MA) of 205.50, below the 50-day MA of 234.12, and below the 200-day MA of 223.94, indicating a bearish trend. The MACD of -11.69 indicates Positive momentum. The RSI at 28.82 is Positive, neither overbought nor oversold. The STOCH value of 7.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UFPT.
Ufp Technologies Risk Analysis
Ufp Technologies disclosed 35 risk factors in its most recent earnings report. Ufp Technologies reported the most risks in the "Macro & Political" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ufp Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $1.47B | 25.04 | 17.36% | ― | 29.47% | 23.24% | |
61 Neutral | $1.55B | -3.28 | -4.63% | ― | -0.23% | ― | |
59 Neutral | $1.73B | 211.68 | 2.44% | ― | 9.81% | -1067.00% | |
56 Neutral | $1.14B | 26.78 | 4.68% | 2.02% | 4.69% | -51.57% | |
56 Neutral | $570.17M | -45.38 | -12.91% | ― | 23.27% | 43.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $744.30M | -1.85 | -39.90% | ― | 4.99% | -7151.40% |
* Healthcare Sector Average
UFPT
Ufp Technologies
190.07
-13.46
-6.61%
CNMD
Conmed
37.08
-22.82
-38.10%
AORT
Artivion
36.12
11.41
46.18%
IART
Integra Lifesciences
9.55
-12.27
-56.23%
AHCO
AdaptHealth
11.39
0.91
8.68%
SIBN
SI-Bone
12.91
-1.13
-8.02%
Ufp Technologies Corporate Events
Business Operations and StrategyFinancial Disclosures
UFP Technologies Updates Investor Presentation on Medical Growth Strategy
Positive
Feb 27, 2026
UFP Technologies has released updated investor presentation materials outlining its business profile and strategic positioning ahead of meetings with investors and other stakeholders. The March 2026 materials detail the company’s emphasis on...
Business Operations and Strategy
UFP Technologies Expands Key Intuitive Surgical Supply Agreement
Positive
Feb 24, 2026
On February 19, 2026, UFP Technologies, through a wholly owned subsidiary, amended its long-standing Manufacturing Supply Agreement with strategic medical customer Intuitive Surgical, effective January 1, 2026. The amendment extends the contract t...
Business Operations and StrategyExecutive/Board Changes
UFP Technologies Finalizes CEO Succession and Executive Compensation
Positive
Feb 13, 2026
UFP Technologies’ board Compensation Committee met on February 10, 2026 to finalize the previously announced succession plan that will see Mitchell C. Rock become chief executive officer on June 4, 2026, approving his employment terms includ...
Business Operations and Strategy
UFP Technologies Highlights Strategic Focus in Investor Update
Positive
Dec 2, 2025
UFP Technologies has released updated presentation materials for investor meetings, highlighting its strategic focus on high-margin, long-term manufacturing opportunities in the medical device market. The company emphasizes its expertise in design...
Business Operations and StrategyExecutive/Board Changes
UFP Technologies Announces CEO Retirement and Succession
Neutral
Dec 2, 2025
On December 1, 2025, UFP Technologies announced the retirement of its long-serving CEO, R. Jeffrey Bailly, effective June 4, 2026. Bailly, who has led the company for 31 years, will transition to the role of Executive Chairman of the Board. Mitche...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.